← All Citius Pharmaceuticals, INC filings

Citius Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CTXR
Citius Pharmaceuticals, INC
10-K/A: Citius Pharma Amends 10-K for Governance, Compensation Details
Citius Pharmaceuticals, Inc. filed an amendment to its annual report to include detailed information on executive compensation, corporate governance, and related party transactions for the fiscal year ended September 30, 2025.
NASDAQ
CTXR
Citius Pharmaceuticals, INC
10-K: Citius Pharma's 2025 Annual Report: LYMPHIR Launch, Financial Challenges
Citius Pharmaceuticals, Inc. reports a net loss of $39.7 million for fiscal year 2025, with its subsidiary Citius Oncology launching LYMPHIR amidst ongoing funding needs and product development.
NASDAQ
CTXR
Citius Pharmaceuticals, INC
10-K/A: Citius Pharmaceuticals Files Amendment No. 1 to Form 10-K, Includes Executive Certifications and Compensation Recovery Policy
Citius Pharmaceuticals files an amendment to its annual report on Form 10-K to include updated executive certifications and a compensation recovery policy.
NASDAQ
CTXR
Citius Pharmaceuticals, INC
10-K: Citius Pharmaceuticals 10-K Filing: Details Capital Structure, LYMPHIR Progress, and Financial Outlook
Citius Pharmaceuticals' annual 10-K filing outlines the company's capital structure, recent reverse stock split, progress with LYMPHIR, and ongoing development of other product candidates, while also highlighting financial risks and future funding needs.